304) nents, which may be responsible for these effects. |
305) 2 and 4 weeks post-injection for adverse effects. |
306) the agriculture, it causes several toxic effects. |
307) can both cause detrimental and beneficial effects. |
308) b demands were expected to moderate these effects. |
309) great concern due to their adverse health effects. |
310) cted of causing adverse male reproductive effects. |
311) raphs, indicating additional non-specific effects. |
312) t achieved remission with no notable side effects. |
313) aling specially for its anti-inflammatory effects. |
314) high specific surface areas and nanosize effects. |
315) ing, anti-inflammatory, and antimicrobial effects. |
316) tal concentrations often have detrimental effects. |
317) opers in order to achieve desired program effects. |
318) n OA cartilage and limit IL-1β catabolic effects. |
319) eficial and could lead to neuroprotective effects. |
320) any mutagenicity, but have antimutagenic effects. |
321) ibition could contribute to its cytotoxic effects. |
322) tifungal, antibacterial and antiparasitic effects. |
323) ibed by a linear growth model with random effects. |
324) ombolytic therapy without serious adverse effects. |
325) llutants on Asian dust days may have skin effects. |
326) body weight (b.w.) induced nonsignificant effects. |
327) tagonists of the AhR may exert protective effects. |
328) specially the pulp, are safe from thermal effects. |
329) several suggested mechanisms for abscopal effects. |
330) HT2C,5-HT3, etc.) roles in antidepressant effects. |
331) e and/or vitamin E alleviated these toxic effects. |
332) dels that have explicitly considered such effects. |
333) and demonstrate attenuated early old-new effects in ASD. |
334) s on nasal, ocular, respiratory, and skin effects in February 2009. |
335) new target molecule that enhances Pa-PDT effects in IHOK and OSCC cell lines. |
336) s characterizing both desired and adverse effects in a modelling framework support e |
|